Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Due to what is seemingly a successful comeback, you can expect Intercept Pharmaceuticals to potentially deliver several-fold returns. Ocaliva's revenue for PBC alone is nearly enough to bank a net profit.

Intercept: Huge Potential Upsides With Binary Catalyst Unlocking

Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.

Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA

The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in Intercept (ICPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?

Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why

MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023. The conference will be held from January 5 – 7, 2023, in Park City, Utah.

Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023

NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study

Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH

MORRISTOWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, is pleased to share that The American Journal of Pathology has published results of a new study evaluating the link between cholestatic liver disease and cognitive impairment in mouse and human cell models. The study, which is the first to explore drug-based treatment response for cholestatic-related cognitive impairment, also evaluated the impact of anti-cholestatic therapies ursodeoxycholic acid (UDCA), obeticholic acid (OCA) and bezafibrate on their potential to reverse cognitive impairment and found that only OCA demonstrated potential efficacy.

New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report?

SAN FRANCISCO--(BUSINESS WIRE)--Today, Komodo Health announced a collaboration with Intercept Pharmaceuticals (Nasdaq: ICPT), powering clinical research and new real-world evidence with Komodo's platform.

Komodo Health's Real-World Evidence and Technology Platform Powers Two Real-World Analyses in Primary Biliary Cholangitis for Intercept Pharmaceuticals

First-in-human data shared at The Liver Meeting® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

The 16.4% sales growth of Ocaliva (obeticholic acid or OCA) over the prior year quarter helped lift shares 13.4%. Presentations next week at The Liver Meeting will give a first clinical look at INT-787.

Intercept Pharmaceuticals' Q3 Call Points To Progress In Revenues, Pipeline

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Global IR Jerome Durso - President, CEO & Director Linda Richardson - EVP & Chief Commercial Officer Michelle Berrey - President, Research & Development and Chief Medical Officer Andrew Saik - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co. Ritu Baral - Cowen Steven Seedhouse - Raymond James & Associates Michael Yee - Jefferies Antonio Arce - H.C. Wainwright & Co. Mayank Mamtani - B.

Intercept Pharmaceuticals, Inc. (ICPT) Q3 2022 Earnings Call Transcript

Investors are cheering the drugmaker's Q3 update.

Why Intercept Pharmaceuticals Stock Is Soaring Today

Intercept (ICPT) delivered earnings and revenue surprises of -159.49% and 2.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates

U.S. Ocaliva® net sales of $77.6 million; 16.4% growth over the prior year quarter

Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation

Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022

MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2022 financial results prior to market open on Tuesday, November 1, 2022. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET.

Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022

Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday. The post Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients appeared first on Investor's Business Daily.

Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients

Today is a big day for Intercept Pharmaceuticals (NASDAQ: ICPT ). The company just announced the clinical-trial results of Intercept's treatment for NASH cirrhosis.

Why Is Intercept Pharmaceuticals (ICPT) Stock Down 20% Today?

Rent-A-Center

Poor earnings and a business setback were costly for these companies.

Nike's Down, but These 2 Nasdaq Stocks Fell Even Further Friday

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.

Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why

Source: Postmodern Studio / Shutterstock Intercept Pharmaceuticals (NASDAQ: ICPT ) stock is on the move Wednesday after giving investors an update on how it improved its financials. A press release from the biopharmaceutical company covers several recent transactions.

News for Intercept Pharma Stock (ICPT)